在白血病中设计儿童低运动功能的物品电池
Francesco Gavazzi1, Sarah Woidill2, Anjana Sevagamoorthy2
1Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USA; Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Molecular genetics and metabolism
|March 5, 2026
概括
儿科低运动功能项目电池 (P-LoMo) 增强了患有白血病的儿童的运动评估. 这种新工具与现有措施有很强的相关性,改善了对严重运动障碍的评估.
科学领域:
- 神经学 神经学
- 儿科医学 儿科医学
- 发育儿科 发育儿科
背景情况:
- 白血病导致髓质质乱,影响中枢神经系统的运动功能.
- 像总运动功能测量-88 (GMFM-88) 这样的标准评估缺乏对深度运动限制的敏感性.
- 需要敏感的工具来评估儿童群体在能力的全部范围内的运动变化.
研究的目的:
- 开发和评估儿科低运动功能的物品电池 (P-LoMo),用于评估严重障碍儿童的运动功能.
- 将结果评估的敏感性扩展到最低的运动能力范围.
- 为儿科患者群体提供可行且与护理人员一致的临床结果评估.
主要方法:
- 通过专家共识,从经过验证的婴儿和儿童运动评估中选择的项目.
- 给168名白血病患者使用P-LoMo和GMFM-88.
- 分析了P-LoMo和GMFM-88分数之间的相关性.
主要成果:
- 在总队列中,P-LoMo与GMFM-88 (斯皮尔曼R = 0.94,p < 0.0001) 显示出强烈的相关性.
- 在GMFM-88表现最低的患者中也观察到高相关性 (斯皮尔曼R = 0.90,p < 0.0001).
- 中位数的P-LoMo得分为71/84,表明它在具有显著运动缺陷的人群中具有实用性.
结论:
- P-LoMo是一种敏感,可行和与护理人员一致的临床结果评估,用于患有白血病和严重运动障碍的儿童.
- 这种工具可以改善试验准备,功能量化和对儿科低运动功能的治疗方法的评估.
- P-LoMo 增强了捕捉弱势儿科群体神经功能全方位的能力.
更多相关视频
相关概念视频
Lysosomal Hydrolases
4.7K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.7K
Pharmacokinetics in Pediatric Patients: Drug Excretion
342
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
342


